Quarterly ResultMay 8, 2026, 05:07 PM
Actinium Pharma Q1 Net Loss Narrows to $5.52M; Cash $42.13M
AI Summary
Actinium Pharmaceuticals reported a significantly reduced net loss of $5.52 million for the first quarter of 2026, a substantial improvement from the $15.94 million net loss in the same period last year. This reduction was primarily driven by a decrease in total operating expenses. The company ended the quarter with $42.13 million in cash and cash equivalents and is actively defending against ongoing legal proceedings.
Key Highlights
- Net loss for Q1 2026 significantly narrowed to $5.52 million from $15.94 million in Q1 2025.
- Net loss per share improved to $(0.18) in Q1 2026 compared to $(0.51) in Q1 2025.
- Cash and cash equivalents were $42.13 million as of March 31, 2026, down from $47.99 million at December 31, 2025.
- Total operating expenses decreased to $5.90 million in Q1 2026 from $16.64 million in Q1 2025.
- Research and development expenses decreased to $4.20 million in Q1 2026 from $7.70 million in Q1 2025.
- General and administrative expenses decreased to $1.70 million in Q1 2026 from $8.94 million in Q1 2025.
- The company has $35 million in long-term deferred license revenue from Immedica Pharma AB.
- Ongoing legal proceedings include a securities class action and derivative complaints related to the Iomab-B Phase 3 Sierra Trial.